NRx Research Pipeline

Our pipeline includes medicinal candidates in Phase 2, and Phase 3 trials for COVID-19-related Lung Injury and Acute Respiratory Distress (ARDS) in partnership with Relief Therapeutics, AG, and the first drug in development to treat Bipolar Depression in Patients with Acute Suicidality.

Opportunities in COVID-19, Respiratory Conditions, and Mental Health.

Indication
Compound Name
Phase
Submission Type
Compound Type
Critical COVID-19 with Respiratory Failure
Intravenous ZYESAMI™ (Aviptadil)
Therapeutic Area: COVID-19
Phase 2/b/3
NDA
Drug
Status
Completed
Study Results
No Results Available
Sponsor/Collaborators
NRx, Inc.|Lavin Consulting, LLC
Locations
St. Jude Medical Center, Fullerton, California, United States|University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Heartland/Mosaic Health, Saint Joseph, Missouri, United States|Hendrick Health, Abilene, Texas, United States|Texas Health Harris Methodist Hospital, Fort Worth, Texas, United States|Texas Health Hospital Frisco, Frisco, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States
Severe COVID-19 with Respiratory Failure
Inhaled ZYESAMI™ (Aviptadil Acetate)
Therapeutic Area: COVID-19
Phase 2/b/3
NDA
Drug
Status
Recruiting
Study Results
No Results Available
Sponsor/Collaborators
NRx, Inc.
Locations
St. Jude Medical Center, Fullerton, California, United States|University of California - Irvine, Irvine, California, United States|University of Louisville Hospital, Louisville, Kentucky, United States
COVID-19 - SPONSORED BY NATIONAL INSTITUTES OF HEALTH
IV ZYESAMI™ (Avipdatil)
Therapeutic Area: COVID-19
Phase 3
NDA
Drug
Status
Recruiting
Study Results
No Results Available
Sponsor/Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)|University of Copenhagen|Medical Research Council|Kirby Institute|Washington D.C. Veterans Affairs Medical Center|AIDS Clinical Trials Group|National Heart, Lung, and Blood Institute (NHLBI)|US Department of Veterans Affairs|Prevention and Early Treatment of Acute Lung Injury (PETAL)|Cardiothoracic Surgical Trials Network (CTSN)|NRx, Inc.|Gilead Sciences
Locations
Duke University Hospital (Site 301-006), 2301 Erwin Road, Durham, North Carolina, United States|University of Utah Health (Site 211-002), 419 Wakara Way, Ste. 207, Salt Lake City, Utah, United States
Severe Bipolar Depression in patients with Acute suicidal ideation
NRX-100/NRX-101™
Therapeutic Area: Bipolar Depression | Suicidal ideation
Phase 2
NDA
Drug
Status
Completed
Study Results
No Results Available
Sponsor/Collaborators
NRx, Inc.|Massachusetts General Hospital|Target Health Inc.
Locations
Research Site, Birmingham, Birmingham, Alabama, United States|Research Site, Fort Lauderdale, Fort Lauderdale, Florida, United States|Research Site, Charlotte, Charlotte, North Carolina, United States|Research Site, Houston, Houston, Texas, United States
Severe Bipolar Depression in patients with Acute suicidal ideation
NRX-101™
Therapeutic Area: Bipolar Depression | Suicidal ideation
Phase 2/b/3
NDA
Drug
Status
Recruiting
Study Results
No Results Available
Sponsor/Collaborators
NRx, Inc.|Target Health Inc.|Vanguard, Inc
Locations
Research Site, Birmingham, Birmingham, Alabama, United States|Research Centers of America, Hollywood, Florida, United States|JP Smith Hospital, Fort Worth, Texas, United States|Research Site, Houston, Houston, Texas, United States
Acute Suicidailty Ideation and Behavior (ASIB) in Bipolar Depression
NRX-100™
Therapeutic Area: Bipolar Depression | Suicidal ideation
Phase 3
NDA
Drug
Status
Recruiting
Study Results
No Results Available
Sponsor/Collaborators
NRx, Inc.|Target Health Inc.
Locations
Research Centers of America, Hollywood, Florida, United States|JP Smith Hospital, Fort Worth, Texas, United States
Moderate Bipolar Depression with Suicidal Ideation
NRX-101™
Therapeutic Area: Bipolar Depression | Suicidal ideation
Phase 2/3
NDA
Drug
Status
Not yet recruiting
Study Results
No Results Available
Sponsor/Collaborators
NRx, Inc.|Target Health Inc.|Bracket, Inc.|Statistics Collaborative, Inc.